Paclitaxel liposomal - Syncore Biotechnology
Alternative Names: EndoTAG-1; MBT-0206; SB 05Latest Information Update: 04 Jan 2024
At a glance
- Originator University of California at San Francisco
- Developer Jules Bordet Institute; MediGene AG; SynCore Biotechnology
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Pancreatic cancer
Highest Development Phases
- Phase III Triple negative breast cancer
- Phase II Pancreatic cancer
- No development reported Colorectal cancer; Gastrointestinal cancer; HER2 negative breast cancer; Liver cancer; Prostate cancer
Most Recent Events
- 04 Jan 2024 No development reported - Phase-III for Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan, USA, Russia, South Korea, Israel, Hungary, France (IV) (Syncore Biotechnology Pipeline January 2024)
- 08 Dec 2022 SynCore Biotechnology terminates Phase-III trial in Triple negative Breast cancer (Metastatic disease, First-line therapy, Combination therapy) in Taiwan (IV) due to study design reconsideration (NCT03002103)
- 19 Feb 2021 Phase III development in Pancreatic cancer (Combination therapy, Second-line therapy or greater) is still ongoing in France, Hungary and Taiwan (IV) (SynCore Biotechnology's pipeline, February 2021)